ID   KP-3L
AC   CVCL_3006
SY   KP-3-L; KP3L; KP-3Ls
DR   CLO; CLO_0037109
DR   BioSample; SAMN03472946
DR   cancercelllines; CVCL_3006
DR   Cell_Model_Passport; SIDM00559
DR   CGH-DB; 177-1
DR   CGH-DB; 9372-4
DR   Cosmic; 918049
DR   JCRB; JCRB0178.1
DR   JCRB; NIHS0275.1
DR   LINCS_LDP; LCL-1724
DR   Wikidata; Q54900368
RX   PubMed=2172194;
RX   PubMed=18380791;
RX   PubMed=21607521;
RX   PubMed=25877200;
RX   PubMed=26216984;
CC   Population: Japanese.
CC   Characteristics: Established from parent cell line through a nude mice tumor.
CC   Doubling time: ~34 hours (Note=Lot 03222016), ~2 days (Note=Lot 06292006) (JCRB=JCRB0178.1).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=21607521).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Glu538Ter (c.1612G>T); ClinVar=VCV000581974; Zygosity=Homozygous (PubMed=18380791).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Metabolome analysis.
CC   Discontinued: JCRB; NIHS0275.1; true.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): JCRB=JCRB0178.1; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 9,13
ST   D18S51: 17
ST   D21S11: 30,32,33
ST   D3S1358: 16,17
ST   D5S818: 13
ST   D7S820: 10,12 (JCRB=JCRB0178.1)
ST   D7S820: 12 (PubMed=25877200)
ST   D8S1179: 13,14
ST   FGA: 23
ST   Penta D: 12,13
ST   Penta E: 15,17
ST   TH01: 6,9.3 (PubMed=25877200)
ST   TH01: 6,10 (JCRB=JCRB0178.1)
ST   TPOX: 9,11 (JCRB=JCRB0178.1)
ST   TPOX: 11 (PubMed=25877200)
ST   vWA: 17,18 (JCRB=JCRB0178.1)
ST   vWA: 18 (PubMed=25877200)
DI   NCIt; C5721; Pancreatic adenosquamous carcinoma
DI   ORDO; Orphanet_424039; Squamous cell carcinoma of pancreas
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3005 ! KP-3
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=2172194; DOI=10.1111/j.1349-7006.1990.tb03336.x;
RA   Ikeda Y., Ezaki M., Hayashi I., Yasuda D., Nakayama K., Kono A.;
RT   "Establishment and characterization of human pancreatic cancer cell
RT   lines in tissue culture and in nude mice.";
RL   Jpn. J. Cancer Res. 81:987-993(1990).
//
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
//
RX   PubMed=21607521; DOI=10.3892/or.1.6.1223;
RA   Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y.,
RA   Shimazoe T., Nawata H., Kono A.;
RT   "Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in
RT   human pancreatic cancer-derived cell-lines with different metastatic
RT   potential.";
RL   Oncol. Rep. 1:1223-1227(1994).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//